Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Partial‐ and Full‐Thickness Skin Burns
We did not find sufficient deviations in the concentrations of ceftolozane/tazobactam to recommend an empiric dose adjustment for patients with burns. However, this finding is limited by our small sample size and lack of clinical outcome data. Therefore, we also provide a conditional recommendation to conduct therapeutic drug monitoring to adjust ceftolozane/tazobactam dosing or to switch to a continuous infusion approach in cases of a suboptimal clinical response.
Authors
- John Griswold (ORCID: https://orcid.org/0000-0002-0578-0646)
- Indhumathy Subramaniyan (ORCID: https://orcid.org/0000-0002-1523-7022)
- Sharmila Dissanaike (ORCID: https://orcid.org/0000-0002-3500-8331)
- Ronald G. Hall (ORCID: https://orcid.org/0000-0002-5616-8246)
- Raja Reddy Kallem (ORCID: https://orcid.org/0000-0003-1859-7063)
- William C. Putnam (ORCID: https://orcid.org/0000-0001-9338-4143)
- Manjunath P. Pai (ORCID: https://orcid.org/0000-0001-7119-5034)
- Levi Hooper (ORCID: https://orcid.org/0000-0002-0537-8702)
Institutions
- Texas Tech University (US)
- University of New Mexico (US)
- University of Michigan (US)
- AbbVie (United States) (US)
- Applied Optimization (United States) (US)
- Therapeutics Clinical Research (US)
- Texas Tech University Health Sciences Center (US)
Publication Details
- Journal
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1002/phar.70076
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 0.00